Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Uber Technologies Inc (UBER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Uber Technologies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Uber Technologies Inc trades at $72.97 (market cap $151.31B). The key difference: Uber Technologies Inc is far larger — about 33.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | UBER | |
|---|---|---|
Market Cap | $4.49B | $151.31B |
Sector | Health | Industrials |
52-Week High | $28.06 | $100.10 |
52-Week Low | $20.06 | $68.61 |
Enterprise Value | $3.69B | $157.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Uber (UBER) trades at $72.42, down 2.7% today, amid a bearish technical signal but strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $52.02 billion, and a net income margin of 15.91%. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, while cost-cutting measures like HR layoffs aim to improve efficiency.
The outlook is mixed: analyst consensus is strongly bullish with a $109.25 price target, but technical indicators and projected 2026 cash flow decline pose risks. Key opportunities include expansion in autonomous driving partnerships; risks involve competitive pressures and execution challenges in new markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
